Japan CORECTIM Market Drug Insight and Market Forecast - 2032

“CORECTIM Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about CORECTIM for Atopic Dermatitis (AD) in Japan. A detailed picture of the CORECTIM for atopic dermatitis in Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the CORECTIM for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CORECTIM market forecast analysis for atopic dermatitis in Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

CORECTIM (delgocitinib) Ointment 0.5% is a non-steroidal topical product and the world's first topical JAK inhibitor that improves AD by inhibiting the action of all members of the JAK family [JAK1, JAK2, JAK3, and tyrosine kinase 2], which play a key role in immune activation signaling in cells, by suppressing the over-activation of immune responses.

In 2014, Leo Pharma and Japan Tobacco (JT) entered into a license agreement in which Leo Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan where JT retains rights (Leo Pharma, 2020).

In October 2016, Japan Tobacco and Torii Pharmaceutical signed an exclusive agreement for co-development and commercialization of JT's original compound, JTE-052 (delgocitinib), for topical use in dermatological indications in Japan. Under the terms of the agreement, JT and Torii would jointly develop JTE-052 in Japan, and the drug will be sold exclusively by Torii in Japan, following its inclusion in the National Health Insurance (NHI) price list. The company has also filed a US patent (Patent No: US20140187534A1), and a worldwide patent (Patent No: WO2011013785A1).

In May 2020, the drug completed a Phase II clinical trial for a period of 8 weeks in adult subjects with AD within the US, however, the results of this trial has not been published yet.

JT has received manufacturing and marketing approval for CORECTIM Ointment 0.25% (delgocitinib) for pediatric AD (aged 2 to < 16) in Japan in March 2021. In addition, JT has received approval for additional pediatric dosage and administration for CORECTIM Ointment 0.5%.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CORECTIM description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on CORECTIM regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CORECTIM research and development activities in atopic dermatitis across Japan.
• The report also covers the patents information with expiry timeline around CORECTIM.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for CORECTIM in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CORECTIM Analytical Perspective

In-depth CORECTIM Market Assessment

This report provides a detailed market assessment of CORECTIM for atopic dermatitis in Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

CORECTIM Clinical Assessment

The report provides the clinical trials information of CORECTIM for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CORECTIM dominance.

• Other emerging products for atopic dermatitis are expected to give tough market competition to CORECTIM and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CORECTIM in atopic dermatitis.
• The in-depth analysis of the forecasted sales data of CORECTIM from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CORECTIM in atopic dermatitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of CORECTIM?
• What is the clinical trial status of the study related to CORECTIM in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CORECTIM development?
• What are the key designations that have been granted to CORECTIM for atopic dermatitis?
• What is the forecasted market scenario of CORECTIM for atopic dermatitis?
• What are the forecasted sales of CORECTIM in Japan?
• What are the other emerging products available and how are these giving competition to CORECTIM for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?

This product will be delivered within 2 business days.